177Lu-PNT6555 by POINT Biopharma Global for Solid Tumor: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

177Lu-PNT6555 overview

177Lu-PNT6555 is under development for the treatment of solid tumor, metastatic colorectal cancer, metastatic adenocarcinoma of the pancreas, metastatic melanoma, head and neck cancer squamous cell carcinoma, gastroesophageal (ge) junction carcinomas, oral cavity (mouth) cancer, oropharyngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, laryngeal cancer
esophageal squamous cell carcinoma (ESCC), soft tissue sarcoma. It consists of radioligand conjugated to lutetium 177. The drug candidate is a D-ala-boroPro based FAP targeting radioligand. It is administered by intravenous route.

POINT Biopharma Global overview

Point Biopharma Global (Point Biopharma), formerly Therapeutics Acquisition Corp, is a radiopharmaceutical company. It develops and commercializes radioligands for cancer. The company is investigating PNT2002 against mCRPC (metastatic castration resistant prostate cancer); PNT2003 program to treat neuroendocrine tumors; PNT2004 targeting solid tumors expressing FAP (fibroblast activation protein); and PNT2001 against prostrate cancer. It utilizes CanSEEK platform technology to develop cancer treatments. The company’s technology aims to minimize toxicity caused by off-target delivery by activating radiopharmaceuticals that target ligands. Point Biopharma is headquartered in Indianapolis, Indiana, the US.

For a complete picture of 177Lu-PNT6555’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.